US. Food and Drug Administration warns patients and healthcare professionals about the use of Fluoroquinolone’s are associated with risk of developing Aortic Aneurysm.
Aortic Aneurysm is an enlargement of the aorta to greater than 1.5 times normal size, with usually no symptoms except when ruptured. This can lead to fatal bleeding.
The fluoroquinolones are the broad-spectrum antibiotics has been in clinical use for 13 years. Some representatives of the class include ciprofloxacin, levofloxacin, Ofloxacin, gatifloxacin, moxifloxacin etc.
They are commonly used for variety of illness such as respiratory and urinary track infections.
Who are on the risk using fluoroquinolones?
Certain patients are at increased risk for aortic aneurysm
- Elderly Patients
- Patients with history of blockages of the aorta or other blood vessels
- High Blood Pressure
- Certain genetic conditions that involve blood vessel changes
The risk aortic aneurysm or dissection is low but twice if prescribed a fluoroquinolone. Risk over benefit is high in these patients, therefore fluoroquinolones should be avoided, and alternative therapy should be given. In some patients with severe bacterial infections such as pneumonia or intra-abdominal infections, fluoroquinolone can be considered with other risk associated with these antibiotics. Always benefit over risk should be considered in all treatment decisions.
The FDA previously communicate the safety information about fluoroquinolones in July 2018 that they significantly decrease in blood sugar and certain mental side effects. In July 2016 it is disabling side effects of tendons, muscles, joints, nerves and CNS (central nervous system) reported. In May 2016 FDA restricted its use for certain uncomplicated infections, in August 2013 FDA reported peripheral neuropathy and in July 2008 fluoroquinolones use involve in tendinitis and tendon rupture.
The FDA said it will continue monitor for any new safety concerns associate with these antibiotics. “The FDA remains committed to keeping the risk information about these products current and comprehensive and will continue to update the public” the FDA Commissioner Scott Gottlieb, M.D. said. ag;\lsdse